The term "compounded GLP" appears constantly in conversations about weight management, metabolic health, and clinic supply chains. But what does it actually mean? And how does it differ from the FDA-approved GLP-1 medications that most people are familiar with?

This post answers those questions directly — covering the definition, the regulatory framework, who can prescribe and dispense compounded GLP preparations, and what clinics need to understand before sourcing them.

GLP-1 stands for glucagon-like peptide-1, a naturally occurring hormone produced in the gut in response to food intake. GLP-1 receptor agonists are drugs that mimic the action of this hormone, stimulating insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite.

FDA-approved GLP-1 receptor agonists include:

• Semaglutide (Ozempic for type 2 diabetes, Wegovy for chronic weight management)
• Tirzepatide (Mounjaro for type 2 diabetes, Zepbound for chronic weight management — a dual GIP/GLP-1 agonist)
• Liraglutide (Victoza for type 2 diabetes, Saxenda for weight management)
• Dulaglutide (Trulicity for type 2 diabetes)
• Exenatide (Byetta, Bydureon for type 2 diabetes)

These are commercially manufactured drugs that have undergone FDA review and approval for specific indications.

A "compounded GLP" medication is a preparation made by a licensed compounding pharmacy that contains a GLP-1 receptor agonist (most commonly semaglutide or tirzepatide) as the active ingredient. It is not an FDA-approved drug — it is a compounded preparation made under the authority of federal and state compounding laws.

Compounded GLP preparations are typically made in one of two ways:

503A compounding: A licensed 503A pharmacy compounds the preparation based on a valid prescription for an individual patient. The preparation is made to order for that specific patient and cannot be made in advance or sold wholesale.

503B outsourcing facility: A registered 503B outsourcing facility manufactures the preparation in larger batches under FDA cGMP oversight. 503B preparations can be sold to licensed healthcare practitioners (clinics, hospitals, etc.) without a patient-specific prescription, though they still require a prescription for dispensing to the patient.

The primary reason compounded GLP preparations exist is drug shortage. When FDA-approved GLP-1 drugs are on the FDA's drug shortage list, federal law (Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act) permits licensed compounding pharmacies to compound preparations containing the same active ingredient.

Semaglutide and tirzepatide were both on the FDA drug shortage list for extended periods due to unprecedented demand. During shortage periods, compounding was explicitly permitted. The FDA has issued guidance on when compounding of shortage drugs is and is not permissible, and the regulatory landscape has evolved as shortage designations have changed.

Clinics sourcing compounded GLP preparations should stay current on the FDA's shortage list and the associated compounding permissions, as these can change.

This is an important nuance. Compounding pharmacies cannot use the finished FDA-approved drug (e.g., Ozempic) as a starting material for compounding. Instead, they use pharmaceutical-grade active pharmaceutical ingredient (API) — the bulk chemical form of semaglutide or tirzepatide — sourced from FDA-registered suppliers.

The API must meet quality standards, and the compounding pharmacy is responsible for verifying the identity, purity, and potency of the API it uses. This is a critical quality control step that distinguishes reputable compounding pharmacies from those that cut corners.

Compounded GLP preparations require a valid prescription from a licensed prescriber, just like any other prescription medication. Licensed prescribers who can prescribe compounded GLP preparations include:

• Medical doctors (MDs)
• Doctors of osteopathic medicine (DOs)
• Nurse practitioners (NPs) with prescriptive authority
• Physician assistants (PAs) with prescriptive authority

The prescription must be for a specific patient and must be issued within a valid prescriber-patient relationship. Prescribers should document the clinical rationale for prescribing a compounded preparation rather than an FDA-approved alternative.

503A pharmacies can dispense compounded GLP preparations directly to patients based on a patient-specific prescription. They cannot sell to clinics for office use without a patient-specific prescription.

503B outsourcing facilities can sell compounded preparations to licensed healthcare practitioners (clinics, hospitals, etc.) for office use. The clinic then dispenses to patients under a valid prescription. This is the pathway that allows clinics to maintain an in-office supply of compounded GLP preparations.

FDA-approved GLP-1 drugs have undergone extensive clinical trials demonstrating safety and efficacy. They are manufactured under strict cGMP standards with rigorous quality controls. The FDA reviews and approves the manufacturing process, the formulation, and the labeling.

Compounded GLP preparations do not have FDA approval. Their quality depends on the compounding pharmacy's practices, quality controls, and compliance with USP standards. Quality can vary significantly between pharmacies.

Key quality factors to evaluate when sourcing compounded GLP preparations:

• Does the pharmacy use API from FDA-registered suppliers?
• Does the pharmacy test each lot for potency and sterility before release?
• Is the pharmacy a 503B outsourcing facility subject to FDA inspection?
• Does the pharmacy provide a Certificate of Analysis (CoA) for each lot?
• What BUD does the pharmacy assign, and is it supported by stability data?

1. Verify the pharmacy's credentials: Confirm the pharmacy is licensed in your state and, if applicable, registered as a 503B outsourcing facility with the FDA.
2. Understand the regulatory landscape: The permissibility of compounding specific GLP-1 drugs depends on FDA shortage designations, which can change. Stay current.
3. Request quality documentation: Ask for CoAs, sterility test results, and stability data for the preparations you source.
4. Ensure valid prescriptions: Every patient receiving a compounded GLP preparation must have a valid prescription from a licensed prescriber.
5. Document everything: Maintain records of the preparations you source, the patients who receive them, and the prescriptions that authorize their use.

1. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA, updated 2024.
2. U.S. Food and Drug Administration. Drug Shortage Database. FDA, accessed 2026.
3. U.S. Food and Drug Administration. Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act. FDA, updated 2024.
4. Federal Food, Drug, and Cosmetic Act, Section 503A (21 U.S.C. § 353a) — Pharmacy Compounding.
5. Federal Food, Drug, and Cosmetic Act, Section 503B (21 U.S.C. § 353b) — Outsourcing Facilities.
6. U.S. Food and Drug Administration. Guidance for Industry: Compounding of Certain Drug Products Under Sections 503A and 503B of the FD&C Act. FDA, 2023.

MedClinic Partners connects licensed clinics and 503A pharmacies with vetted 503B supply and USA-made cGMP RUO peptides. Questions about compounded GLP access? Use the Get Connected form to reach our team.